ationa! Application No
/US2004/024334

A. CLASSIF	ICATION OF SUBJECT MATTER C07D263/20 C07D413/06 C07D413/	12 A61K31/421 A6	51K31/422		
According to	International Patent Classification (IPC) orto both national classification	tion and IPC			
B FIELDS					
Minimum do IPC 7	commentation searched (classification system followed by classification $C07D - A\delta 1 \ K$	n symbols)			
Documentation	on searched other than minimum documentation to the extent that su	ich documents are included in the fiel	ds searched		
Electronic da	ata base consulted during the international search (name of data bas	e and, where practical, search terms	used)		
EPO-Inte	ernal , WPI Data, CHEM ABS Data				
C. DOCUME	NTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No		
Y	EP 0 694 543 A (BAYER AG) 31 January 1996 (1996-01-31)		1-8, 10-17, 20-23, 26-45		
	page 91 - page 94; claim 1 page 83; examples 124,125 page 2, line 3 - line 4				
Y	EP 0 352 781 A (E.I. DU PONT DE N AND COMPANY) 31 January 1990 (199		1-8, 10-17, 20-23, 26-45		
	page 2, line 4 - line 6				
		-,/			
X Furt	ther documents are listed in the continuation of box C	X Patent family members are l	isted in annex		
° Special ca	ategories of cited documents	'T" later document published after the	international filing date		
consid	ent defining the general state of the art which is not lered to be of particular relevance document but published on or after the International	or priority date and not in conflict cited to understand the principle invention	with the application but or theory underlying the		
filing of L ¹ docume which	date nt which maythrow doubtson priority clarn(£) or is cited to establish the publication date of another	'X' document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y' document of particular relevance, the claimed invention			
O" docume other	n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means	cannot be considered to involve document is combined with one ments, such combination being	an inventive step when the or more other such docu-		
later t	ent published prior to the international filing date but than the priority date claimed	in the art '&' document member of the same patent family			
_	actual completion of the international search	Date Of mailing of the international 2 4. 11. 2005	l search report .		
	August 2005				
Name and	mailing address of the ISA European Patent Office, P B 5818 Patentlaan 2 NL - 2280 HV Rijswijk	Authorized officer			
ł	Tel (+31-70) 340-2040, Tx 31 651 epo nl, Fax (+31-70) 340-3016	Fink, D			

Fom PCT/ISA/210 (second sheet) (January 2004)

iational Application No -/US2004/024334

C.(Continuati	on) DOCUMENTS CONSIDERED TO BE RELEVANT	-/US2004/024334
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Category	Charton of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	BRICKNER S J: "OXAZOLIDINONE ANTIBACTERIAL AGENTS" CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 2, 1996, pages 175-194, XP001007528 ISSN: 1381-6128 the whole document; in particular, page 187, Figure (2); and page 189, col umn 2, l ast paragraph - page 190, col umn 2, Table I X	1-8, 10-17, 20-23, 26-45
A	wo 01/94342 A (DONG A PHARM. CO., LTD; LEE, JAE-GUL; LEEM, WON-BIN; CHO, JONG-HWAN; C) 13 December 2001 (2001-12-13) page 163 - page 170; claim l page 107; example 80 page 98; example 63 page 1, paragraph 1	1-8, 10-17, 20-23, 26-45
X	wo 01/81350 A (ASTRAZENECA AB; ASTRAZENECA UK LIMITED; GRAVESTOCK, MICHAEL, BARRY; BE) 1 November 2001 (2001-11-01) page 127 - page 134; claim 1	1-8, 12, 14, 16, 20, 22, 26-34, 41-43
Е	page 139; claim 12 wo 2005/012271 A (RIB-X PHARMACEUTICALS, INC; WU, YUSHENG; CHEN, SHILI; CHEN, YI; HANSEL) 10 February 2005 (2005-02-10)	1-6,8, 10, 11, 13-17, 26-30, 32-45
	page 66 - page 68; examples 6,7; compounds 66,67 page 75 - page 78; exampl e 13; compounds 155, 156	
Е	wo 2005/019211 A (RIB-X PHARMACEUTICALS, INC; ZHOU, JIACHENG; BHATTACHARJEE, ASHOKE; CHE) 3 March 2005 (2005-03-03) page 173 - page 176; example 13; compounds 96,97 page 192; example 27; compound 127 page 217 - page 219; example 54; compound 402	1-6,8, 10, 11, 13-17, 30, 32-45

Form PCT/ISA/210 (cont nuation of second sheet) (January 2004)

ternational application No PCT/US2004/024334

Box 11 Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons
l Claims Nos because they relate to subject matter not required to be searched by this Authority, namely
Claims Nos because they relate b parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically see FURTHER INFORMATION sheet PCT/ISA/210
3 j I Claims Nos because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a)
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application as follows see additi onal sheet
1 As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims
2 J As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee
3 I I As only some of the required additional search fees were timely paid by the applicant, this International Search Report 1—1 800-vpcrrss and/vy thhousage ethalimnss form withinchin 1995 Wherripe passidd Septe-Cittle-Lander-y Chadimanss Nooss
4 In No required additional search fees were timely paid by the applicant Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos See annex
Remark on Protest The additional search fees were accompanied by the applicant's protest No protest accompanied the payment of additional search fees

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II. 2

Present claims 1-45 relate to "prodrugs" of the compounds of the present general formula.

The term "prodrug" is considered to lead to a lack of clarity within the meaning of Article 6 PCT because this term does not comprise any information as regards the structure of the compounds concerned. It is therefore impossible to compare the said "prodrug" compounds with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the said "prodrugs" have not been searched.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

the compounds of the present claim 1 wherein Het-CH2-R3 represents a 5-(R3-CH2)-2-oxo-oxazolidin-3-y1 group and A and B are phenyl ;

2. claims: 1-4 (all partly), 8 (partly), 10-13 (partly) and 26-45 (all partly);

the compounds of the present claim 1 wherein Het-CH2-R3 represents a 5-(R3-CH2)-2-oxo-oxazolidin-3-y1 group, A is phenyl, B is selected from pyridyl, pyrazinyl, pyriitiidinyl and pyridazinyl, X is -NR4-, and M is other than formyl and Cl-4acyl;

3 . claims: 1-4 (all partly), 8 (partly), 10-13 (partly), 26-29 (all partly) and 32-45 (all partly);

the compounds of the present claim 1 wherein Het-CH2-R3 represents a 5-(R3-CH2)-2-oxo-oxazolidin-3-y1 group, A is phenyl, B is selected from pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl, and X is -NR4NR4-;

4 . claims: 1-4 (all partly), 8 (partly), 10-13 (partly), 26-29 (all partly) and 32-45 (all partly);

the compounds of the present claim 1 wherein Het-CH2-R3 represents a 5-(R3-CH2)-2-oxo-oxazolidin-3-yl group, A is phenyl, B is selected from pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl, and X is -S-;

the compounds of the present claim 1 wherein Het-CH2-R3 represents a 5-(R3-CH2)-2-oxo-oxazolidin-3-yl group, A is selected from pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl, B is phenyl, and X is -NR4- or -NR4NR4-;

6. cl aims: 1-7 (al I partly) , 9-15 (al I partly) , 18, 19, 20 (partly), 21 (partly) , 24, 25, 26-29 (al I partly) and 32-45 (al I partly) ;

FURTHER INFORMATION CONTINUED FROM PCTASA/ 210

the compounds of the present claim 1 wherein Het-CH2-R3 represents a 5-(R3-CH2)-2-oxo-oxazolidin-3-y1 group, A is selected from pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl, B is phenyl, and X is -S-, and M is other than acetyl;

- 7. claims: 1 (partly), 4-12 (all partly) and 26-45 (all partly);

 the compounds of the present claim 1 wherein Het-CH2-R3 represents a 2-(R3-CH2)-5-oxo-isoxazolin-4-yl group;
- 8. claims: 1 (partly), 4-12 (all partly) and 26-45 (all partly);
 the compounds of the present claim 1 wherein Het-CH2-R3
 represents a 5-(R3-CH2)-isoxazolin-3-yl group;
- 9. claims: 1 (partly), 4-12 (all partly) and 26-45 (all partly);

 the compounds of the present claim 1 wherein Het-CH2-R3 represents a 5-(R3-CH2)-2-oxo-5H-furan-3-yl group;

Information on patent family members

iational Application No 7US2004/024334

			7032004/024334		
Patent document cited in search report	Publication date		Patent family member(s)		Publication date
EP 0694543 A	31-01-1996	AU	699940	B2	17-12-1998
		AU		A	01-02-1996
		BG		Α	30-04-1996
		CA		Al	21-01-1996
		CN		Α	03-04-1996
		CZ		A3	14-02-1996
		DE		Al	04-04-1996
		DZ	1912	-	17-02-2002
		EE		A	15-02-1996
		FI		A	21-01-1996
		HR		Al	30-04-1997
		HU		A2	28-03-1997
		IL		A	17-08-1999
		JP		A	13-02-1996
				Al	01-04-1996
		MA		A	22-01-1996
		NO		A	
		NZ			29-01-1997 22-01-1996
		PL		Ai Bl	
		RO			30-12-1999
		S.K.		A3	07-02-1996
		US		A	06-05-1997
		ZA	9506018	A	13-03-1996
EP 0352781 A	A 31-01-1990	ΑŬ	622465	B2	09-04-1992
		ΑU	3911589	Α	01-02-1990
		CA	1337526	C	07-11-1995
		DK	374389	Α	30-01-1990
		FI	893618	Α	30-01-1990
		HU		A2	28-01-1992
		ΙE	892438	L	29-01-1990
		JP	2124877	Ā	14-05-1990
		ĴР	2899319	B2	02-06-1999
		NO		A	30-01-1990
		NZ		Ā	25-10-1991
		PT		Ā	08-02-1990
		US	4948801	A	14-08-1990
		ZA	8905778	A	27-03-1991
wo 0194342	A 13-12-2001	AU	5889701	A	17-12-2001
		BR	0111280	Ā	10-06-2003
		CA	2411859	Al	13-12-2001
		CN		A	30-07-2003
		EP		Al	12-03-2003
		ΗU	0301562	A2	29-12-2003
		JР	2003535860	T	02-12-2003
		MX	PA02012045		15-10-2003
		NZ		Ā	29-08-2003
		US	2003166620	Al	04-09-2003
wo 0181350	A 01-11-2001	AT	268778	T	15-06-2004
WU U1U1JJU .	. 01 11-2001	AU	781784	B2	16-06-2005
		AU- ,	10.00.	A	07-11-2001 -
		BR	0110240	A	07-01-2001
		CA	2405349	Al	01-11-2001
		CN	1437603	A	20-08-2003
		CZ	20023527	A3	15-01-2003
		DE	60103754	Dl	15-07-2004
			(11) (1) 7 / 14	1.71	1. コーロフームしりが
		DE	60103754	T2	16-06-2005

Information on patent family members

atlonal Application No
/US2004/024334

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
wo 0181350	Α.		DK	1286998	Т3	06-092004
			EE	200200598	Α	15-042004
			ΕP	1286998	Al	05-032003
			ES	2220759	T3	16-12- - 2004
			HК	1053114	Al	18-02-2005
			HU	0300416	A2	28-062003
			JР	2003531211	\mathbf{T}	21-102003
			MX	PA02010453	A	25-04 2003
			NO	20025091	A	09-12-~2002
			ΝZ	521765	A	28-052004
			PL	358326	Al	09-082004
			PT	1286998	T	30-092004
			TR	200402261	T4	21-12-2004
			US	2003216373	Al	20-112003
			ZA	200208187	A	11-022004
WO 2005012271	Α	10-02-2005	NONE			
WO 2005019211		03-03-2005	NONE			